PneumoNIX Medical Inc.

BALTIMORE, MD · Medtech · Private

Injectable hydrogel biosealant and delivery device for sealing needle tracts during CT-guided lung biopsies

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Headquarters
BALTIMORE, MD
Total capital
$1.4M
Federal grants
$1.4M
2 awards · 2019–2022
Rank in peer group#421 of 538
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
3
9 pending · first 2021
Rank in peer group#158 of 538

Capital timeline

2019202020212022FEDERAL ↑EQUITY ↓Cumulative $1.4M$225K$1.2M
2019202020212022FEDERAL ↑EQUITY ↓Cumulative $1.4M$225K$1.2M

Latest events

  • Federal grantNSF · Phase II · SBIR Phase II:Preventing Pneumothorax During Lung Biopsy Using a Novel Hydrogel$1.2M
  • Federal grantNSF · Phase I · SBIR Phase I: Preventing Pneumothorax During Lung Biopsy Using Novel Hydrogel$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#158 · top 29%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 3 granted of 12
  • GrantedApparatus And Method To Seal A Tissue TractUSPTOUS 12,193,651
  • PendingMethods And Material Compositions For Preventing Non-target EmbolizationUSPTOApplication 18675318
  • PendingMethods And Material Compositions For Sealing A TractUSPTOApplication 18290042
Show all 12 patent records
  • Apparatus And Method To Seal A Tissue TractJan 14, 2025 · US 12,193,651Granted
  • Methods And Material Compositions For Preventing Non-target EmbolizationDec 5, 2024 · Application 18675318Pending
  • Methods And Material Compositions For Sealing A TractSep 26, 2024 · Application 18290042Pending
  • Apparatus And Method To Seal A Tissue TractMay 2, 2023 · US 11,638,578Granted
  • Tissue Tract Sealant DeviceNov 9, 2021 · US D,935,611Granted
  • Apparatus And Method To Seal A Tissue TractApplication PCTUS2018062799Pending
  • Method and Apparatus for Preventing PneumothoraxApplication 62591193Pending
  • Methods And Material Compositions For Sealing A TractApplication 19487152Pending
  • Methods And Material Compositions For Sealing A TractApplication PCTUS2024030756Pending
  • Methods And Material Compositions For Preventing Non-target EmbolizationApplication 63469938Pending
  • Methods And Material Compositions For Sealing A TractApplication 63468313Pending
  • Methods And Material Compositions For Sealing A TractApplication PCTUS2022028756Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .